The deal begins commercialization of Emosis' first test for heparin-induced thrombocytopenia in at least 36 countries that recognize CE marking.
IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.
The company said it also saw record cash collections in the quarter despite challenges caused by regulatory change.
The effort could lead to Metafora's flow cytometry-based assay becoming the standard of care for diagnosing the disease in France.
The flow cytometry-based HIT Confirm test is a first-in-class functional test that provides results in 30 minutes, according to Emosis.
The assay correlates shortened telomere lengths in patients of different ages to potential risks for inherited diseases, such as bone marrow failure syndrome and liver cancer.
BD alleges Cytek hired away former BD employees to develop flow cytometry products to compete against BD.
According to CEO Eugene Chan, the CE designation is just the first of more to come, as the company enters the diagnostics market with a focus on hematological testing.
Through the new lab, NeoGenomics can work with pharmaceutical clients through the different phases of drug development, including the development of companion diagnostics.
The firm has been offering its StatRes test through a deal with St. Joseph Health and is now looking to sign similar agreements with other hospital systems.